Shares of Jubilant Life Sciences today surged 12.5 per cent after the company said its subsidiary has signed long-term contracts in the US for the supply of some of its diagnostic and therapeutic products.
Following this, the stock zoomed 12.55 per cent to Rs 717.95 on the BSE.
On the NSE, shares of the company jumped 12.5 per cent to Rs 717.80.
During the morning trade, 5.81 lakh shares of the company were traded on the BSE and over 37 lakh shares changed hands on the NSE.
In a BSE filing, Jubilant Life Sciences said, “Its wholly-owned subsidiary Jubilant Pharma, through one of its units, Jubilant DraxImage Montreal Canada (JDI), has signed long-term contracts with distribution networks in the US for supply of products used for diagnostic and therapeutic procedures for thyroid, myocardial perfusion, lungs, kidney and bone scans to be supplied by JDI over 39 months effective January 2017.”
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.